Roche has declared  that Emicizumab (Hemlibra®) has been approved in India for Hemophilia A with factor VIII inhibitors. It is indicated as a prophylactic(preventive) treatment to prevent or reduce the frequency of bleeding episodes. Hemlibra is the first weekly subcutaneous (under the skin) prophylaxis injection shown to prevent or reduce the frequency of bleeding episodes and improve the quality of life. 

It is designed to bring together factor IXa and factor X proteins required to activate the natural coagulation cascade and restore the blood clotting process for people with Hemophilia A. 

All current prophylactic treatment options for people with Hemophilia A with factor VIII inhibitors require intravenous infusions several times a week. Even then, some people may experience joint bleeds that can lead to long-term damage. 

The approval of Emicizumabis an important advancement for the entire Hemophilia A community. It is a first-in-class of treatments for people with severe Hemophilia A, with inhibitors in nearly 20 years. The clinical evidence of Hemlibra is supported by a comprehensive and extensive development program in Hemophilia A across all ages. 

“The introduction of Emicizumab(Hemlibra®) is a significant milestone in the treatment of Hemophilia A in India and reaffirms our commitment to bring Roche's groundbreaking medicines to patients in India asearlyas possible,” said Lara Bezerra, Chief Purpose Officer (MD), Roche Pharma India. “This break-through medicine represents a completely new way to manageHemophilia Aand redefines the standard of care. With this new therapy, patients now have a stronger chance of leading ahealthy and active life.”

 Hemlibra is approved by multiple regulatory authorities across the world and is now also approved and available in India.